Celgene Amends Complaint In Thalomid Spat

Law360, New York (October 3, 2007, 12:00 AM EDT) -- Pharmaceutical company Celgene Corp. has launched another attack in its ongoing crusade to protect cancer drug Thalomid from generic competition, filing an amended complaint in the pending patent litigation against generic maker Barr Laboratories.

Filed on Tuesday in the U.S. District Court for the District of New Jersey, the complaint reasserts allegations that Barr's proposed generic version of Thalomid would violate eight of Celgene's patents for the drug.

The amended complaint adds a newly granted patent to the suit, which is also the subject of a...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.